TENAYA THERAPEUTICS INC. - COMMON STOCK

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

02 May 2023 06:50:18 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

21 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

08 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

07 Feb 2023 16:17:05 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones

09 Jan 2023 06:00:02 By Nasdaq GlobeNewswire

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

07 Dec 2022 15:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

28 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

23 Nov 2022 08:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Closing of Public Offering

21 Nov 2022 16:45:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Pricing of Public Offering

16 Nov 2022 23:39:47 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Proposed Public Offering

16 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

10 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022

04 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress

04 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions

29 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences

29 Sep 2022 06:45:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

06 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction

06 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

10 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure

06 Jul 2022 13:00:00 By Nasdaq GlobeNewswire